• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wagner Scott

    (Last) (First) (Middle)
    C/O GOODRX HOLDINGS, INC.
    2701 OLYMPIC BOULEVARD

    (Street)
    SANTA MONICA CA 90404

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GoodRx Holdings, Inc. [ GDRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    11/30/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 11/30/2023 P 21,652 A $5.7642(1) 182,900 I By Wagner Family Trust(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.70 to $6.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
    2. Shares held directly by the Wagner Family Trust (the "Trust"). The Reporting Person and his spouse serve as trustees of the Trust, and the Reporting Person, his spouse and other members of his immediate family are the sole beneficiaries of the Trust.
    Remarks:
    /s/ Gracye Cheng, Attorney-in-Fact for Scott Wagner 12/04/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/25/2024$7.50 → $10.00Equal Weight → Overweight
    Wells Fargo
    3/1/2024$7.00 → $10.00Neutral → Overweight
    JP Morgan
    2/26/2024$8.00Outperform
    Leerink Partners
    More analyst ratings

    $GDRX
    Financials

    Live finance-specific insights

    See more
    • GoodRx Reports First Quarter 2025 Results

      First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

      5/7/25 4:13:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

      GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

      4/9/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Reports Fourth Quarter and Full Year 2024 Results

      Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of $44.7 million Exited the quarter with over 7 million consumers of pr

      2/27/25 6:05:00 AM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Idea Men, Llc converted options into 7,000,000 shares and returned $29,400,000 worth of shares to the company (7,000,000 units at $4.20) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      3/21/25 4:23:24 PM ET
      $GDRX
      EDP Services
      Technology
    • Large owner Spectrum Equity Vii, L.P. converted options into 3,000,000 shares and returned $12,600,000 worth of shares to the company (3,000,000 units at $4.20) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      3/18/25 4:23:43 PM ET
      $GDRX
      EDP Services
      Technology
    • Large owner Francisco Partners Iv, L.P. converted options into 10,000,000 shares and returned $42,000,000 worth of shares to the company (10,000,000 units at $4.20) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      3/18/25 4:18:20 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on GoodRx with a new price target

      Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00

      12/4/24 7:38:07 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx upgraded by Raymond James with a new price target

      Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00

      8/9/24 7:30:17 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded GoodRx from Sector Perform to Outperform and set a new price target of $10.00 from $8.00 previously

      5/23/24 7:39:11 AM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GoodRx Reports First Quarter 2025 Results

      First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

      5/7/25 4:13:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

      GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

      4/9/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Introduces New E-commerce Experience for Retail Pharmacies

      Company working with Hy-Vee as launch partner to simplify how consumers get their medications through the GoodRx platform GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced a new e-commerce experience for retail pharmacies that improves how consumers get their medications via the GoodRx platform. The company is launching the experience with Midwest-based retailer Hy-Vee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250403717682/en/GoodRx e-commerce experience Now, when a person searches for their medication on GoodRx and selects Hy-Vee as their preferred pharmacy, the system will che

      4/3/25 9:00:00 AM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

      Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

      3/17/25 9:00:00 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer

      Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role. Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthca

      2/5/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology
    • WM Technology, Inc. Names Sarah Griffis Chief Technology Officer

      WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Sarah Griffis as the Company's new Chief Technology Officer, effective January 6, 2025. "I am thrilled to welcome Sarah as our new CTO. She has great experience not just building and leading engineering and tech teams, but also operating in regulated industries like ours," said Doug Francis, Chief Executive Officer at Weedmaps. "I look forward to partnering with her and the rest of our tech org to continue delivering innovative and best-in-class technology solutions to our customers." Prior to joining W

      1/6/25 9:00:00 AM ET
      $GDRX
      $MAPS
      EDP Services
      Technology
      Computer Software: Prepackaged Software

    $GDRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by GoodRx Holdings Inc.

      10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

      5/7/25 4:50:11 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

      5/7/25 4:25:29 PM ET
      $GDRX
      EDP Services
      Technology
    • SEC Form DEFA14A filed by GoodRx Holdings Inc.

      DEFA14A - GoodRx Holdings, Inc. (0001809519) (Filer)

      4/23/25 4:22:08 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/14/24 12:29:56 PM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/13/24 4:30:24 PM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/12/24 4:02:41 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      12/4/23 4:35:10 PM ET
      $GDRX
      EDP Services
      Technology
    • Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      11/30/23 4:41:35 PM ET
      $GDRX
      EDP Services
      Technology
    • Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      11/17/23 7:08:30 PM ET
      $GDRX
      EDP Services
      Technology